Chemical biology for drugging undruggable targets
Public support
Provider
Ministry of Education, Youth and Sports
Programme
—
Call for proposals
—
Main participants
Ústav organické chemie a biochemie AV ČR, v. v. i.
Contest type
OP - EU Operational Programme
Contract ID
16_019/0000729-01
Alternative language
Project name in Czech
Chemická biologie pro vývoj nových terapií
Annotation in Czech
Cílem výzkumné agendy je vývoj nových potenciálních terapeutik rakoviny, virových onemocnění a metabolických poruch na principu specifické inhibice tzv. "undruggable" interakcí biomakromolekul, na které klasická medicinální chemie nedosáhne. Výzkum bude zaměřen na tři klíčové typy biomolekulárních interakcí: (1) protein-protein (VP1); (2) protein-membrána (VP2) a (3) protein-DNA či protein-RNA (VP3).
Scientific branches
R&D category
ZV - Basic research
OECD FORD - main branch
10401 - Organic chemistry
OECD FORD - secondary branch
30107 - Medicinal chemistry
OECD FORD - another secondary branch
10608 - Biochemistry and molecular biology
CEP - equivalent branches <br>(according to the <a href="http://www.vyzkum.cz/storage/att/E6EF7938F0E854BAE520AC119FB22E8D/Prevodnik_oboru_Frascati.pdf">converter</a>)
CC - Organic chemistry<br>CE - Biochemistry<br>EB - Genetics and molecular biology<br>FP - Other medical fields
Completed project evaluation
Provider evaluation
U - Uspěl podle zadání (s publikovanými či patentovanými výsledky atd.)
Project results evaluation
The project aimed to make breakthroughs in the treatment of cancer, viral infections and metabolic disorders by targeting undruggable targets. New principles and inhibitors of protein-protein, protein-membrane and protein-nucleic acid interactions were investigated and discovered, including identification of candidates for drug development. Significant advances have been made in the development of insulin mimetics and analogues targeting the insulin and IGF-1 receptor to enable regulation of metabolic pathways. Results have also been achieved in the area of STING receptors, where new types of agonists and antagonists have been discovered, as well as antibody conjugates with potential for cancer therapy. The algorithms for the design of peptide ligands have shown high agreement of binding property estimates with experimental results, representing a significant step towards the design and development of therapeutics against cancer and viral diseases.
Solution timeline
Realization period - beginning
Jan 1, 2018
Realization period - end
Feb 28, 2023
Project status
U - Finished project
Latest support payment
Sep 6, 2020
Data delivery to CEP
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data delivery code
CEP24-MSM-EF-U
Data delivery date
Jul 1, 2024
Finance
Total approved costs
458,361 thou. CZK
Public financial support
458,361 thou. CZK
Other public sources
0 thou. CZK
Non public and foreign sources
24,851 thou. CZK